Clinical Trial Update: Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating low-dose ipilimumab in combination with pembrolizumab for metastatic melanoma with brain metastases has completed, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases
• Melanoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Yervoy (ipilimumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Status: COMPLETED | Results posted: 2026-01-09